MeiraGTx (MGTX) investor relations material

Executive summary

• FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for Grade 2/3 radiation-induced xerostomia, supported by 3-year Phase 1 data.

• Strategic collaborations with Eli Lilly and Hologen AI brought significant upfront and milestone payments, expanding the pipeline and providing non-dilutive financing.

• Multiple late-stage clinical programs advanced, including AAV-GAD for Parkinson's (RMAT designation) and riboswitch gene regulation platform.

Financial highlights

• Cash, cash equivalents, and restricted cash were $68.2M as of Dec 31, 2025, down from $105.7M at year-end 2024.

• Service revenue for 2025 was $6.4M, down from $33.3M in 2024, due to completion of PPQ services for Johnson & Johnson.

• License revenue was $75.0M in 2025, reflecting the upfront payment from the Lilly collaboration.

• Net loss attributable to ordinary shareholders for 2025 was $114.2M ($1.42 per share), improved from $147.8M ($2.12 per share) in 2024.

• Research and development expenses increased to $129.6M in 2025 from $119.5M in 2024, mainly due to higher manufacturing and clinical program costs.

Outlook and guidance

• Sufficient capital to fund operations into the second half of 2027, including repayment of $75M in debt due by May 2027.

• Expects potential BLA filing for AAV2-hAQP1 in H1 2027, with possible US launch in early 2028.

• Anticipates initiation of Phase 3 AAV-GAD study for Parkinson's in coming months.